![Taimur Shah, [object Object]](/_next/image?url=https%3A%2F%2Fd3fzwscyjtgllx.cloudfront.net%2Fuploads%2Fimages%2F3553617150773400076897.jpg&w=3840&q=60)
FAQs
M. Taimur Shah est un chirurgien urologique expérimenté expérimenté spécialisé dans un large éventail de conditions urologiques, en mettant l'accent sur les traitements pour l'hyperplasie bénigne de la prostate.
Mr Taimur Shah is an experienced Consultant Urological Surgeon and Clinical Senior Lecturer (Associate Professor) at Imperial College London where he leads the prostate cancer multidisciplinary team. His expertise includes a wide range of urological conditions, with a focus on treatments for benign prostatic hyperplasia.
Education
Mr Shah earned his medical degree from University College London in 2007, as well as a first-Class honours degree in molecular medicine. He later undertook his specialist urology training at Charing Cross Hospital, The Royal Marsden Hospital, Barnet and Chase Farm Hospitals, and the Whittington Hospital. Following this, he pursued a uro-oncology fellowship in robotic surgery at Guys and St Thomas Hospital. He is a Fellow in Urology of the Royal College of Surgeons and holds a PhD from UCL.
Specialties
Internationally recognised, Mr Shah specialises in investigating prostate cancer with advanced techniques such as MRI and fusion transperineal prostate biopsies. Additionally, Mr Shah is at the forefront of employing cutting-edge, minimally invasive methods for treating prostate cancer, including Da Vinci robotic prostatectomy, high intensity focused ultrasound (HIFU) and cryotherapy as part of focal therapy.
Awards and Accolades
Alongside his clinical work, Mr Shah has several publications in peer-reviewed journals within the area of urology and prostate cancer. Mr Shah is a sought-after speaker, having been invited to deliver lectures on national and international platforms.
Research Interests
Mr Shah’s current research focuses on focal therapy using HIFU and cryotherapy for newly diagnosed prostate cancer and cases that have recurred after previous radiotherapy. He has actively contributed to the design and implementation of multiple clinical trials addressing primary, metastatic, and radio-recurrent prostate cancer. Currently, he is a valuable member of the Imperial Prostate Group at Imperial College London
MBBS - University College London, UK in 2007
BSc (Hons) Molecular Medicine - University College London, UK
MRCS - Royal College of Surgeons, UK
FRCS (Urol) - Royal College of Surgeons, UK
PhD - University College London, UK
